Evgen Pharma Plc Grossly undervalued say Northland Capital Partners

15th Feb 2017

Evgen Pharma Plc (LON:EVG) are the topic of conversation with Northland Capital Partners head of Research Vadim Alexandre. Vadim explains the importance of news that a first patient has been dosed in the Company’s Phase II clinical trial of SFX-01 in breast cancer and also talks about Evgen’s prospects over the next few years.

Directors Talk exclusive interview with Vadim Alexandre, Head of Research Northland Capital Partners Limited.


Evgen Pharma Plc is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. It is also carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. The Company’s core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. The company commenced operations in January 2008 and is based in Liverpool, UK, at the Liverpool Science Park. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.